Adverse Event: Adverse events related to this study are minimal because the patient will have an intravenous line placed for the surgery whether or not she consents. In addition, all patients receive preoperative antibiotics prior to the surgical delivery so receiving a medication in this fashion is already being done. Furthermore, obtaining cord blood does not involve any laboratory blood draws on the newborn. (No study has ever evaluated the acetaminophen level in cord blood though levels in the newborn following oral administration have not been higher than the maternal levels. The reports on patient levels in other studies have not been in the toxic range following a single administration of 1000 mg. Therefore, though never studied, it is not expected that the cord blood levels will be above the therapeutic range. The molecular weight of acetaminophen is 151 Daltons with a bioavailability of about 75% and a half-life of 1 to 4 hours. Based on these parameters, the drug would be expected to cross into and out of the fetus fairly easily similar to penicillin, creating a fairly steady state within the mother and fetus.) Although adverse events are not expected in either the mother or neonate, the study investigators will be responsible for monitoring any adverse events should that become necessary. Evaluation of maternal and neonatal liver and kidney function is not necessary as the mother will only receive one dose of acetaminophen, 1000 gms, which is considered a normal adult dose.